SRX3305

Overview

SRX3305 is an BTK/PI3K/BRD4 inhibitor with IC 50 s of 6.5 nM, 15 nM, and 4 nM toward BTK , PI3Kɑ and PI3Kδ , respectively. SRX3305 attenuates chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) cell proliferation and promotes apoptosis in a dose-dependent fashion. SRX3305 yields potent anti-tumor effects but spares healthy bystander cells. SRX3305 inhibits the activation-induced proliferation of primary CLL cells in vitro and effectively blocks microenvironment-mediated survival signals. SRX3305 blocks CLL cell migration toward CXCL-12 and CXCL-13 . SRX3305 maintains its anti-tumor effects in Ibrutinib ( HY-10997 )-resistant CLL cells. SRX3305 can be used for research in CLL, diffuse large B-cell lymphoma (DLBCL) and MCL.

Application

Products | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PI3K | Products > Signaling Pathways > Btk | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-182671
• CAS No.: 2409965-28-0
• Molecular Formula: C22H20N2O5S
• Molecular Weight: 424.47
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source